FRA has signed onto a letter to the Chairs and Ranking Members of the House and Senate Subcommittees on Defense Appropriations to provide funding for the treatment-focused Gulf War Illness Research Program (GWIRP), part of the Congressionally Directed Medical Research Program (CDMRP) within the Department of Defense (DoD). Peer-reviewed studies have consistently concluded that Gulf War Illness (GWI) affects approximately 25-32% of the veterans of the 1990-91 Gulf War. GWI is characterized by multiple, diverse symptoms that typically include chronic headache, widespread pain, cognitive difficulties, debilitating fatigue, gastrointestinal problems, respiratory symptoms, sleep problems, and other abnormalities that could not be explained by established medical diagnoses or standard laboratory tests.